{"filings":[{"id":2079756,"accession_number":"0001654954-26-007306","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2026-08-05T20:30:26+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q2 revenue $9.5M (+37% YoY), net loss down 49% to $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue of $9.5M, up 37% YoY; net loss reduced 49% to $3.8M from $7.4M.","Diagnostics segment revenue grew 77% to $1.4M; Therapeutic Devices up 9% to $6.8M.","Cash burn improved 38% to $3.4M; operating expenses down 20% to $10.1M.","Cash and securities $44.1M; 22nd consecutive quarter of YoY revenue growth.","Development Services segment contributed $1.4M in Q2, $3.4M YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":18311000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000360,"accession_number":"0001654954-26-005904","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2026-06-11T20:15:41+00:00","items":["5.07","9.01"],"status":"ready","headline":"Zomedica shareholders reject advisory vote on executive compensation at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight director nominees elected; Grant Thornton LLP ratified as auditor for 2026 with 403.3M for.","Say-on-pay proposal failed: 129,290,109 against vs. 99,891,977 for; broker non-votes 200,401,613.","By-law amendment on quorum requirements for adjourned meetings approved: 123,410,315 for, 105,771,772 against.","All director nominees (Rowe, Cohen, Macleod, Nichols, Powers, Whelan, Williams, Heaton) elected with majority support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94676,"accession_number":"0001654954-26-004419","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q1 revenue record $8.8M, up 35% YoY; net loss narrows to $4.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue $8.8M, up 35% from $6.5M in Q1 2025; 21st straight quarter of YoY growth.","Diagnostics segment revenue $1.0M, +73% YoY; Therapeutic Devices $5.8M flat; Development Services $2.0M.","Net loss $4.5M vs $63.8M in prior year which included $55.8M impairment; Adjusted EBITDA loss improved 58% to $2.4M.","Cash burn reduced 15% to $5.7M; liquidity $47.5M as of March 31, 2026.","Launched TRUVIEW AI telepathology platform and announced collaboration with Boehringer Ingelheim for equine PPID testing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":8799000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107232,"accession_number":"0001654954-26-002304","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports record Q4 revenue $10.5M, full-year revenue $32.0M (+17% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $10.5M (+33% YoY); full year $32.0M (+17%). Record 20th straight YoY increase.","Gross margin 68% for year; Q4 69% best quarter. Adjusted EBITDA loss improved to $17.1M from $20.2M.","Cash burn reduced to $18.1M for year, $1.1M in Q4; cash/securities $53.3M.","Consumable revenue grew 16% to $20.7M; Development Services segment contributed $3.1M.","Net loss $81.9M includes $55.8M non-cash impairment; operating expenses ex-impairment down 7%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123570,"accession_number":"0001654954-25-012575","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q3 2025 revenue $8.1M (+16% YoY); net loss narrows to $6.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.1M, up 16% YoY; gross margin 67%; Diagnostics segment grew 51%.","Net loss $6.1M (down 9% YoY); adjusted EBITDA loss $3.9M.","Cash and securities $54.4M; operating expenses reduced $0.5M in Q3.","New Development Services segment generated $0.7M revenue in first quarter.","Record revenue for 19th straight quarter; new distribution agreements in UK, Netherlands, Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":21559000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140247,"accession_number":"0001654954-25-009136","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q2 revenue up 14% to $7M; Diagnostics segment jumps 86%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.0M, up 14% YoY; gross margin 67%, consistent with prior period.","Diagnostics segment revenue $0.8M (+86%), driven by TRUFORMA platform adoption.","Net loss $7.4M vs $23.9M (including $16M impairment) in Q2 2024; Adj. EBITDA loss $5.5M.","Operating expenses down $0.7M excluding impairment; liquidity $59.1M.","Record 18th consecutive quarter of YoY revenue growth; consumable sales up 21%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":13464000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157905,"accession_number":"0001654954-25-006839","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Zomedica shareholders reject advisory vote on executive compensation at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Advisory vote on NEO compensation failed: 56.7M for, 82.4M against, 32.3M abstain.","All eight director nominees elected; Larry Heaton received lowest support (85.3M for, 86.1M against).","Ratification of Grant Thornton LLP as auditor for 2025 approved with 310.6M votes for.","Meeting held June 10, 2025; results disclosed in Form 8-K filed June 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157904,"accession_number":"0001654954-25-005749","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q1 revenue $6.5M (+4% YoY), net loss $63.8M on $55.8M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.5M (+4% YoY); gross margin 68% vs 66% in Q1 2024.","Net loss $63.8M includes $55.8M non-cash impairment from share price decline.","Adjusted EBITDA loss $5.7M vs $5.3M in Q1 2024; cash & securities $64.6M.","Consumables revenue up 13% to $4.5M; Diagnostics down 25% to $0.6M.","Shares outstanding 979.9M; liquidity down from $71.4M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":6500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157903,"accession_number":"0001654954-25-004863","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Scott Jordan resigns; VP Finance Michael Zuehlke assumes interim role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Jordan resigned as CFO effective April 25, 2025; receives $80,769 lump sum and 3 months COBRA reimbursement.","Michael Zuehlke (VP Finance and Corporate Controller) will handle accounting/finance operations until a permanent CFO is hired.","Mr. Jordan intends to return to his consulting firm S. Jordan Associates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176280,"accession_number":"0001654954-25-002744","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports record Q4 revenue $7.9M, full year $27.3M; net loss narrows to $7.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $7.9M (+8% YoY); full year $27.3M, also up 8% from 2023.","Gross margin 70.3% for Q4 and 70.0% for full year, at high end of 65-70% guidance.","Net loss improved to $7.2M in Q4 from $22.4M a year ago; full year net loss $47.0M vs $34.5M.","Diagnostics segment revenue surged 109% YoY in Q4 driven by TRUFORMA and VETGuardian adoption.","Cash, equivalents and securities $71.4M; adjusted non-GAAP EBITDA loss $20.2M for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176279,"accession_number":"0001654954-25-002296","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Zomedica delisted from NYSE American, to trade on OTCQB starting March 5 under ZOMDF","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American suspended trading March 4, 2025 due to low share price under Section 1003(f)(v).","Company expects trading on OTCQB under symbol ZOMDF effective March 5, 2025.","CEO Larry Heaton stated disappointment but emphasized focus on growth and pipeline.","Company will continue to file periodic reports with the SEC and meet regulatory requirements.","Transition does not affect business or operations; real-time trading data remains available via OTC Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193168,"accession_number":"0001654954-24-015750","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zomedica appoints Scott Jordan as CFO effective Jan 1, 2025; base salary $350K plus options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Jordan appointed Executive VP Finance and CFO, effective January 1, 2025.","Jordan has over 30 years in life sciences/diagnostics; founded S. Jordan Associates.","Compensation includes $350K base salary, up to 40% bonus, 5M share options vesting over 4 years.","Succeeds Peter Donato, who departed as CFO in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193167,"accession_number":"0001654954-24-014663","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zomedica enters new 15,371 sq ft lease for Ann Arbor HQ through Jan 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with 1101 Technology Drive, L.L.C. commences Feb 1, 2025, replacing prior lease.","Initial term ends Jan 31, 2030; two five-year renewal options on same terms.","Tenant pays utilities and proportionate share of expenses/taxes with 5% annual cap.","Base rent amount not disclosed in filing summary; full terms in Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193166,"accession_number":"0001654954-24-014016","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q3 revenue up 10% to $7.0M; gross margin 72.3%; diagnostics segment grows 38%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.0M (+10% YoY); gross margin 72.3% above 65-70% guidance.","Diagnostics segment revenue $0.5M (+38% YoY); Therapeutic Device $6.5M (+9%).","Net loss $6.7M vs $0.5M loss a year ago (prior year included $2.2M acquisition gain).","Adjusted non-GAAP EBITDA loss $4.3M; operating cash burn ~$5.2M, adjusted $4.0M.","Cash & securities $77.8M at Sept 30, down from $83.0M at June 30; no guidance change."],"consensus_eps_estimate":0.0,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":19390000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209541,"accession_number":"0001654954-24-010666","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports record FY2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY2024 $31-35M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2023 revenue $7.3M (+19% YoY); FY2023 revenue $25.2M (+33% YoY), driven by Diagnostics (+252%) and Therapeutic Devices (+28%).","Gross margin 69% for FY2023; consumable revenue $16.4M (+41% YoY), 65% of total revenue.","Net loss $34.5M ($0.035/share) vs $17.0M in FY2022; Adjusted Non-GAAP EBITDA loss $12.8M.","Cash and securities $100.5M at Dec 31, 2023; reiterated FY2024 revenue guidance $31-35M.","Acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies in 2023; launched TRUVIEW and new assays."],"consensus_eps_estimate":0.0,"consensus_eps_actual":-0.034,"consensus_revenue_estimate":null,"consensus_revenue_actual":12393000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209540,"accession_number":"0001654954-24-010665","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zomedica CFO Peter Donato resigns; VP Finance Zuehlke steps in as interim","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Peter Donato resigned effective Aug 15, 2024; enters 3-year consulting agreement for transition.","VP of Finance & Corporate Controller Michael Zuehlke assumes interim operational responsibility for accounting and finance.","Donato receives $20,312.50 flat fee for first 3 months (10 hrs/week) then $250/hr; 3-year consulting term.","Separation agreement includes mutual release, confidentiality, non-disparagement, and reimbursement of $27,500 for leased home.","Company conducting third-party search to replace Donato as CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227633,"accession_number":"0001654954-24-007515","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Zomedica shareholders reject advisory vote on executive compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisory 'say-on-pay' resolution failed: 79,412,285 for vs. 88,436,460 against, plus 183,131,919 broker non-votes.","All eight director nominees elected; votes ranged from 103.6M to 117.6M for, with broker non-votes of ~183.1M.","Ratification of Grant Thornton LLP as auditor for 2024 passed: 288,330,513 for, 67,093,805 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227632,"accession_number":"0001654954-24-005886","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q1 revenue up 14% to $6.3M, net loss widens to $9.2M; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $6.3M (+14% YoY) driven by 86% growth in Diagnostics and 9% in Therapeutic Devices.","Net loss $9.2M ($0.01/share) vs $6.4M loss in Q1 2023; adjusted non-GAAP EBITDA loss $6.2M.","Gross margin 66%; consumable revenue $4.0M (64% of sales), capital revenue $2.2M (+30% YoY).","Cash and securities $90.9M at March 31, 2024, down from $100.5M at Dec 31, 2023.","FY 2024 revenue guidance maintained at $31-35M, up ~39% at high end from $25.2M in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.009,"consensus_revenue_estimate":null,"consensus_revenue_actual":6262000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227631,"accession_number":"0001654954-24-004239","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports record FY 2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY 2024 revenue $31-35M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $7.3M (+19% YoY); full-year revenue $25.2M vs $18.9M in 2022.","Gross margin 69% for both Q4 and full year 2023; consumable revenue grew 41% to $16.4M.","Net loss $34.5M ($0.035 per share) vs $17.0M ($0.017) in 2022; adjusted non-GAAP EBITDA loss $12.8M.","Cash and securities $100.5M as of Dec 31, 2023; operating cash burn adjusted for one-time items ~$2.6M in Q4.","FY 2024 revenue guidance $31-35M (up to 40% YoY); growth driven by recent product launches and acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.009,"consensus_revenue_estimate":null,"consensus_revenue_actual":6262000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246429,"accession_number":"0001654954-24-003187","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Zomedica continues NYSE American listing dialogue after shareholder rejection of reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American deficiency letter Sept 2023 for 30-day avg share price below $0.20 per Section 1003(f)(v).","Shareholders rejected proposed 80:1 reverse stock split at Feb 28, 2024 special meeting; 67.7% majority required.","Shares remain listed; exchange will monitor price and further deterioration could trigger delisting.","CEO Larry Heaton cites progress and opportunities to positively impact share price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246428,"accession_number":"0001654954-24-002358","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zomedica shareholders reject 80-for-1 reverse stock split at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share Consolidation Proposal required two-thirds approval; received only 39.44% 'for' votes.","Final vote: 136,067,529 (39.44%) For, 206,789,223 (59.95%) Against, 2,109,080 (0.61%) Abstain.","Proposal not approved; company retains no shareholder authorization for reverse split.","The reverse split was likely intended to address NYSE American minimum bid price compliance.","Failure to approve may increase risk of delisting from NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263859,"accession_number":"0001654954-23-014163","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q3 revenue up 31% to record $6.3M; net loss narrows to $0.3M; NYSE listing deficiency","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $6.3M, up 31% YoY; gross margin 69%, up from 67% sequential.","Net loss narrowed to $0.3M ($0.001/share) from $5.8M ($0.005/share) a year ago.","Non-GAAP EBITDA loss $0.3M vs $3.0M loss; adjusted non-GAAP EBITDA profit $0.3M.","Liquidity $118M; completed acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies.","NYSE American notified of low share price deficiency; 30-day avg <$0.20; company plans cure."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.012,"consensus_revenue_estimate":null,"consensus_revenue_actual":17849000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263858,"accession_number":"0001654954-23-012710","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Zomedica acquires Qorvo Biotechnologies, maker of TRUFORMA platform, for undisclosed sum","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Purchase price not disclosed; acquisition includes QBT's manufacturing and R&D staff in Plymouth, MN.","Deal eliminates future license fees, transition fees, and royalties due to QBT under prior agreement.","Zomedica assumes QBT's manufacturing line, aiming for margin improvements and accelerated assay development.","Zomedica updated long-term supply agreement with Qorvo Inc. for BAW sensors.","Company considering strategic options for human health portion (Omnia platform) to focus on veterinary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281076,"accession_number":"0001654954-23-011829","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Zomedica gets NYSE American deficiency notice for low share price (<$0.20 avg)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["30-trading day average share price fell below $0.20, triggering Section 1003(f)(v) non-compliance.","Cure deadline is March 12, 2024; Company may effect a reverse stock split.","No immediate delisting; shares continue trading on NYSE American during cure period.","Management remains well-capitalized; business operations and SEC reporting unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281075,"accession_number":"0001654954-23-011572","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Zomedica closes $18M acquisition of Structured Monitoring Products, maker of VetGuardian","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of SMP for $18M enterprise value; paid $12.66M in cash after debt conversion and adjustments.","Converted $2.75M convertible debt into SMP equity valued at $5.1M, converting 28.7% stake.","Cash purchase funded from $12.4M cash on hand; $250K deposit previously paid.","VetGuardian is a touchless vital signs monitor for pets; to be manufactured in Roswell, GA.","Zomedica plans international launch and distribution through its sales team and animal health distributors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281074,"accession_number":"0001654954-23-010493","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q2 revenue up 43% to $6.0M; net loss flat at $5.3M; cash $142.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.0M vs $4.2M YoY (+43%); therapeutic segment $5.8M (+38%), diagnostic $0.2M (+100%).","Net loss $5.3M ($0.005/sh) unchanged YoY; adjusted non-GAAP EBITDA loss $3.1M.","Cash & equivalents $142.4M, down from $186.8M YoY; normalized operating burn ~$3M.","Gross margin 67%; adjusted >70% excluding one-time costs; consumable revenue $4.0M (+48% YoY).","Due diligence on potential SMP (VetGuardian) acquisition progressing; TRUVIEW digital microscopy launched late June."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.012,"consensus_revenue_estimate":null,"consensus_revenue_actual":11502000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299787,"accession_number":"0001654954-23-008016","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Zomedica shareholders elect all eight directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; votes for ranged from 83.9M to 87.7M, with 198.5M broker non-votes each.","Ratification of Grant Thornton LLP as auditor for 2023: 275.4M for, 19.4M against, 0 abstain.","Advisory vote on named executive officer compensation approved: 72.6M for, 20.6M against, 3.2M abstain, 198.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299786,"accession_number":"0001654954-23-006220","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q1 revenue up 45% to $5.5M; net loss widens to $6.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.5M (+45% YoY); gross margin 70%; net loss $6.4M ($0.007/share) vs $3.9M loss a year ago.","Diagnostic segment revenue $0.4M (+300% YoY); Therapeutic segment $5.1M (+38% YoY).","Cash and securities $147.5M; cash used in Q1 was $8.3M including $4.0M TRUFORMA licensing fees.","Paid $250k non-refundable deposit to exercise acquisition option for Structured Monitoring Products (VetGuardian).","Amended Georgia lease to add 6,000 sq ft for TRUFORMA cartridge manufacturing; TRUVIEW digital microscopy system launch planned in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.007,"consensus_revenue_estimate":null,"consensus_revenue_actual":5482000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299785,"accession_number":"0001654954-23-006129","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Zomedica expands Roswell facility by 6,000 sq ft, extends lease term","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease amendment adds 6,000 rentable sq ft to existing 12,400 sq ft at 4000 Northfield Way, Roswell, GA.","Lease term extended to 60 months after earlier of delivery of expansion space or December 1, 2023.","Expansion Premises monthly base rent starts at $6,250 (months 1-12) and rises to $7,311.62 (months 49-60).","Existing Premises monthly base rent from May 2027 is $14,529.49, increasing to $15,110.67 in months 49-60."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299784,"accession_number":"0001654954-23-005950","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zomedica exercises option to acquire Structured Monitoring Products for $18M enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exercised option to buy SMP, maker of VetGuardian remote monitoring system, at $18M enterprise value.","Paid a non-refundable $250k deposit toward the purchase price; 120-day due diligence period begins.","Zomedica invested $2.75M in convertible notes in May 2022, Jan and Mar 2023, which included this option.","VetGuardian is a zero-touch vital signs monitor; Zomedica has been distributing it since January 2023.","Deal includes a sublicense for human use rights to a NewCo entity, with royalties to University of Florida Research Foundation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319889,"accession_number":"0001654954-23-003129","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zomedica appoints Peter Donato as CFO effective March 16, 2023; Ann Marie Cotter resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ann Marie Cotter resigned as CFO effective March 16, will remain through April 15 for transition.","Cotter receives 12 months base salary, prorated bonus, and stock option acceleration under separation agreement.","New CFO Peter Donato has 30+ years experience; previously CFO at Standard Bariatrics acquired by Teleflex.","Donato's compensation: $325k base salary, up to 40% annual bonus, $35k relocation bonus, and options for 5M shares.","Options vest over four years; change-of-control severance includes one year salary and COBRA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319888,"accession_number":"0001654954-23-002947","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports 2022 revenue of $18.9M, up 361% YoY; net loss narrows to $17.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.9M, up 361% from $4.1M in 2021; 72% gross margin.","Net loss $17.0M vs $18.4M in 2021; improvement of $1.4M (8%).","Cash, equivalents and securities $156M at Dec 31, 2022; no SVB/Signature exposure.","PulseVet small-animal device sales grew 405% in 2022; VetGuardian launched; TRUVIEW expected Q2 2023.","Acquisitions of Assisi and Revo Squared contributed; evaluating further M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319887,"accession_number":"0001654954-23-001545","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica sees Q4 rev $6.0-6.2M (+46-51% YoY); FY rev up ~360%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue expected $6.0-$6.2M, +46-51% vs Q4 2021, driven by PulseVet and Assisi.","Full-year 2022 revenue expected $18.6-$18.9M, +354-361% over 2021.","Gross margin for FY 2022 expected ~72%.","Cash, cash equivalents and available-for-sale securities ~$156M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.017,"consensus_revenue_estimate":null,"consensus_revenue_actual":18930000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319886,"accession_number":"0001654954-23-000712","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Zomedica restructures TRUFORMA deal with Qorvo; takes control of development and manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ZomInc pays $4M up-front license fee and up to another $4M upon cartridge production line qualification.","Option to extend exclusive TRUFORMA rights for veterinary use perpetually for $8M one-time fee.","ZomInc to take over assay development and manufacturing at Roswell, GA facility over ~18 months.","Prior Development Agreement terminated with no early termination penalties.","Zomedica Corp guarantees all obligations of ZomInc under each agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319885,"accession_number":"0001654954-23-000603","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zomedica begins commercializing VetGuardian wireless vital signs monitor via distribution deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zomedica subsidiary entered distribution agreement with Structured Monitoring Products for VetGuardian remote monitor.","VetGuardian uses patented doppler tech to monitor temperature, pulse, and respiration contact-free.","Deal follows prior note purchase agreement; two-year term with automatic 12-month renewals.","Zomedica will purchase products for resale and share service fees; no financial terms disclosed.","CEO cites improved patient care and staffing relief as key benefits for veterinary clinics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338098,"accession_number":"0001654954-22-015279","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q3 revenue $4.78M, net loss $5.0M; cash $158.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $4.78M (vs $0.02M Q3 2021); gross margin 75%.","Net loss $5.0M ($0.005/shr) vs $6.35M loss prior year.","Cash, equivalents, and AFS securities $158.5M at Sep 30, 2022.","Closed acquisitions of Revo 2 imaging assets and Assisi LOOP/Calmer Canine product lines.","PulseVet small animal unit sales up 225% YoY; TRUFORMA revenue up 350% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.014,"consensus_revenue_estimate":null,"consensus_revenue_actual":12773000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355459,"accession_number":"0001654954-22-011771","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-08-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zomedica appoints Dr. Pamela Nichols to board; grants 800K stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from six to seven members; Dr. Nichols fills new vacancy.","Dr. Nichols is immediate past president of American Animal Hospital Association (2020-2021).","She will serve on Audit and Compensation Committees; granted options for 800,000 common shares vesting over four years.","Founded six veterinary hospitals and dog boarding facilities; received DVM from Colorado State University.","Appointment effective August 23, 2022; she will stand for election at 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355458,"accession_number":"0001654954-22-011401","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q2 2022 revenue $4.2M, up 51% pro-forma; net loss $5.3M, cash $186.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.2M (71% gross margin), up 51% pro-forma vs combined $2.8M in Q2 2021.","PulseVet revenue $4.2M (+48% standalone); small animal systems sold 22 (20x increase).","Net loss $5.3M ($0.005/sh) vs $4.7M loss in Q2 2021; 6-month loss $9.2M ($0.009/sh).","Cash $186.8M; used $5.5M in quarter including $1M convertible note in SMP (VetGuardian).","Post-quarter acquisitions: Revo 2 imaging assets and Assisi LOOP/Calmer Canine products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.009,"consensus_revenue_estimate":null,"consensus_revenue_actual":7997000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355457,"accession_number":"0001654954-22-009891","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-07-20T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"Zomedica acquires Assisi Animal Health for $18M cash plus warrants","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired substantially all assets of Assisi Animal Health for $18.0M cash and a 10-year warrant for 22M common shares at $0.252 per share.","Acquisition closed July 15, 2022; deal includes escrow for indemnification ($1.4M) and post-closing adjustments ($200k).","Assisi produces tPEMF devices (Loop, Loop Lounge, DentaLoop, Calmer Canine) that reduce pain and inflammation in companion animals.","Products complement Zomedica's PulseVet shock wave therapy and extend at-home care by pet owners.","Over 100,000 pets treated with Assisi products since 2013; supported by peer-reviewed studies and veterinary opinion leaders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355456,"accession_number":"0001654954-22-009489","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zomedica announces new 12,400 sq ft global manufacturing & distribution center in Roswell, GA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New 12,400 sq ft facility to more than double capacity; construction completion expected August 2022.","Facility will consolidate manufacturing and distribution for PulseVet, TRUFORMA, Revo 2, and VetGuardian.","Lease: 61 months, $9,300/month first 12 months, escalating to $11,315/month.","CEO Larry Heaton cites growing product sales as driver for expansion.","COO Tony Blair: new center leverages existing workforce to improve manufacturing footprint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355455,"accession_number":"0001654954-22-009486","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["2.01","3.02","1.01","8.01","9.01"],"status":"ready","headline":"Zomedica closes acquisition of Revo Squared for $6M cash plus warrants, earn-outs up to $4M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed acquisition of Revo Squared on July 1, 2022 for $6M base cash, subject to working capital adjustments.","Issued 10-year warrant to Revo Squared for 10M common shares at $0.2201 per share.","Earn-out payments up to $4M: $2M each when Revo net sales exceed $5M and $10M in any calendar year through 2027.","Revo's MicroView digital cytology platform automates slide preparation; manufacturing moving to Roswell, GA facility.","Company expects to launch MicroView to veterinary market in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373627,"accession_number":"0001654954-22-008585","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zomedica acquires Revo Squared veterinary imaging assets for $6M cash plus earn-out and warrants","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Base purchase price $6M cash, subject to working capital adjustments; $500K held in escrow for 15 months.","Up to $4M in earn-out payments based on net sales milestones ($2M each for $5M and $10M threshold) through 2027.","Warrants to purchase 10M common shares issued at closing; exercise price tied to ZOM closing price on closing date.","Acquisition includes MicroView digital cytology platform, an automated slide preparation and imaging system for veterinary clinics.","Closing expected on or around July 1, 2022; Revo Squared CEO Bill Campell and Senior Director Negin Ghassemian to join Zomedica."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373626,"accession_number":"0001654954-22-008381","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zomedica appoints Anthony K. Blair as COO and Karen DeHaan-Fullerton as Chief Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony K. Blair appointed COO effective June 13, 2022; base salary $250K with up to 35% annual performance bonus.","Karen DeHaan-Fullerton appointed Chief Counsel and Corporate Secretary; base salary $250K with up to 30% annual bonus.","Blair previously EVP Operations since Jan 2022; prior roles include COO of Cardiox and VP at Neoprobe.","DeHaan-Fullerton had been General Counsel since May 2022; prior experience at Exactech and Elanco.","Both retain previously granted stock options (Blair: 3M shares at $0.35; DeHaan-Fullerton: 500K at $0.24) with four-year vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373625,"accession_number":"0001654954-22-008148","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zomedica annual meeting results: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six directors elected; Rodney Williams had highest withhold at 28.6% (85M for, 34M withheld).","Grant Thornton LLP appointed as auditor with 97.4% approval (286.8M for, 7.7M withheld).","Advisory say-on-pay passed with 80.3% for (93.5M for, 23.0M against, 2.6M abstain).","Shareholders chose annual frequency for future say-on-pay votes (84.9% for 1 year).","Turnout: 294.6M shares (30.1% of outstanding) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373624,"accession_number":"0001654954-22-006382","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q1 revenue $3.8M, up 38% pro forma; net loss $3.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.8M (74% gross margin) vs $14K in Q1 2021; up 38% over combined Zomedica+PulseVet $2.7M.","PulseVet revenue $3.7M (+36% vs standalone Q1 2021); small animal unit sales 30 (+500% YoY).","TRUFORMA product revenue $57K (+307% vs $14K); launched endogenous ACTH assay in April 2022.","Cash $192.3M at quarter end; net loss $3.9M ($0.004/share) vs $36.0M loss in Q1 2021.","SG&A $6.7M (+91% YoY) driven by share-based comp and sales force expansion; R&D $351K."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.004,"consensus_revenue_estimate":null,"consensus_revenue_actual":3751000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392311,"accession_number":"0001654954-22-002346","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports 2021 full-year revenue of $4.1M; net loss $18.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $4.1M in 2021, vs $0 in 2020; gross margin 73.9%.","Net loss $18.4M ($0.05 diluted EPS) vs $16.9M ($0.19) in 2020.","PulseVet Q4 revenue $4.0M, up 66% YoY as standalone; TRUFORMA Q4 revenue $73k, up 224% QoQ.","Cash and equivalents $195M at Dec 31, 2021 vs $62M a year earlier.","Expected to launch eACTH assay in Q2 2022; evaluating M&A opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4133123.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410634,"accession_number":"0001654954-21-013049","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K/A","filed_at":"2021-12-10T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Zomedica files pro forma financials for Pulse Veterinary acquisition; $71.9M cash price","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Preliminary purchase price of $71.9M funded from cash; pro forma cash after deal $197.7M.","Pro forma 2020 net loss $13.4M, including $1.5M amortization on acquired intangibles.","Acquired intangible assets valued at $33.65M with 11-19 year useful lives; goodwill $44.9M.","Branford PVT generated $7.1M revenue in 2020 and $8.5M in 9mo 2021; combined entity net loss.","Audited financial statements of Branford PVT filed as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410639,"accession_number":"0001654954-21-012630","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2021-11-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zomedica CCO Bruk Herbst departs; separation agreement with benefits for termination without cause","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruk Herbst separated from Zomedica as Chief Commercial Officer effective Nov 19, 2021.","Separation agreement provides benefits for termination without cause per his employment agreement and home office equipment (excluding laptop).","Agreement includes mutual release of claims, confidentiality, non-disparagement, and non-solicitation obligations.","Herbst had 21 days to consider and 7 days to revoke the agreement; it was signed on Nov 19, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410638,"accession_number":"0001654954-21-012392","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Zomedica discloses 10b5-1 trading plans covering up to 8.06M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three directors, one executive officer, and other employees adopted Rule 10b5-1 plans for the period Jan 1–Dec 31, 2022.","Plans cover a maximum of 8,061,842 common shares, including 7,101,842 shares from outstanding stock options.","Plans were adopted for long-term financial planning, retirement, and diversification; trades are pre-arranged but not guaranteed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410637,"accession_number":"0001654954-21-012080","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q3 net loss $6.3M; revenue minimal from TRUFORMA launch; cash $271.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.3M ($0.01/share) vs $5.0M loss in Q3 2020; nine-month loss $15.1M.","Revenue from TRUFORMA products was $22,514; commercial launch began March 2021.","Cash and equivalents $271.4M at Sept 30, 2021; pro forma after PulseVet acquisition ~$199.5M.","SG&A expense rose 166% to $6.1M, driven by share-based compensation and PulseVet deal costs.","R&D expense fell 89% to $0.3M as initial TRUFORMA assays completed; development shifts to commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":52000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-12T23:59:59+00:00|410637"}